Treatment of the disease includes both risk factor modification and efforts to improve blood flow to the lower extremity. For mild to moderate intermittent claudication, medical therapy as well as a supervised exercise program is advised. For debilitating claudication or critical limb ischemia, a ...
Inhibitors of the adhesion of monocytes to oxidised low density lipoprotein or other lipid raft ligand for the therapy or prophylaxis of a condition involving monocyte adhesion to oxidised LDL or other lipid raft ligand, such as atherosclerosis, rheumatoid arthritis, multiple sclerosis or glomerulonephrit...
Drugs for treatment of patients with high cholesterol blood levels and other dyslipidemias. Atherosclerotic coronary artery disease (ASCAD) is the most common cause of morbidity and mortality in most developed nations. Dyslipidemia increases the risk of ASCAD. Diet, lifestyle habits, and/or lipid-...
Accurate disease characterization and monitoring are critical for therapeutic planning and epidemiological records. However, most traditional diagnostic procedures involving pathological examination of biopsies cannot precisely detect the disease state in real-time and are time-consuming. Thus, there is an ...
was approved by the FDA in 2013 for the treatment of homozygous familial hypercholesterolemia, a rare life-threatening condition characterized by markedly elevated circulating levels of low-density lipoprotein cholesterol (LDL-C) and accelerated, premature atherosclerotic cardiovascular disease122,123. This ...
Adams HP Jr, del Zoppo G, Alberts MJ, et al; American Heart Association; American Stroke Association Stroke Council; Clinical Cardiology Council; Cardiovascular Radiology and Intervention Council; Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working ...
For this purpase, it is important to evaluate not only the presence or absence of coronary artery disease (CAD) and the LDL-C level, but also other coexisting major risk factors, i.e., atherosclerotic disorders other than CAD such as cerebrovascular diseases and arteriosclerosis obliterans, and...
For example, a recent study presented a magnetic mesoporous nanoparticle functionalized with VCAM-1-targeted VHPKQHR peptide for MR imaging of atherosclerotic plaque [67]. In comparison to non-VCAM-1 targeted peptide conjugated nanoparticles, VHPKQHR nanoparticles efficiently interacted with VCAM-1 ...
Impact of brief exercise on circulating monocyte gene and microRNA expression: Implications for atherosclerotic vascular disease. Brain Behav Immun 2014; 39: 121–129. Article CAS PubMed PubMed Central Google Scholar Di Raimondo D, Tuttolomondo A, Buttà C, Casuccio A, Giarrusso L, Miceli G ...
The goals of treatment are to reduce mortality and morbidity, prevent heart disease or its progression, and manage comorbidities that cause and/or contribute to the pathogenesis of heart failure. Despite considerable therapeutic advances, treatment of acute decompensated heart failure has not changed muc...